

Haematologica
HAEMATOL/2017/171884
Version 4

Labile plasma iron levels predict survival in patients with lower-risk
Myelodysplastic syndromes

Louise de Swart, Chloé Reiniers, Timothy Bagguley, Corine van Marrewijk, David Bowen, Eva Hellström-Lindberg, Aurelia Tatic, Argiris Symeonidis, Gerwin Huls, Jaroslav Cermak, Arjan A. van de Loosdrecht, Hege Garelius, Dominic Culligan, Mac Macheta, Michail Spanoudakis, Panagiotis Panagiotidis, Marta Krejci, Nicole Blijlevens, Saskia Langemeijer, Jacqueline Droste, Dorine W. Swinkels, Alexandra Smith, and Theo de Witte

Disclosures: Consultant or advisory role: ASY Novartis, Sanofi-Aventis, Genesis-Pharma, Amgen, Teva, Bristol, Janssen-Cilag, TDW Novartis, Celgene; honoraria: TDW Novartis; research funding: ASY Novartis, Sanofi-Aventis, Genesis-Pharma, Amgen, Glaxo-Smith Cline, Bristol, Actellion, EH Celgene, TDW Novartis.

Contributions: Design: LDS, AS, TB, TDW; provision of patients, assembly of data: LDS, CR, TB, CM, DB, EHL, AT, ASY, GH, JC, AVL, HG, DC, MM, MS, PP, MK, NB, SL, JD, DS, AS, TDW; data analysis: LDS, CR, TB, CM, DB, DS, AS, TDW; manuscript writing: all authors; final approval: all authors.